Adakveo Injection
Product Images NDC 0078-0883

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Adakveo (NDC 0078-0883). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Preparation And Administration (Seg101 01)

This text seems to be a formula for calculating the volume of a medication called ADAKVEO based on the patient's body weight and prescribed dose. However, some characters are unreadable making the formula incomplete and its functionality not available.*

FDA Label Image

Principal Display Panel Ndc 0078-0883-61 Rx Only Adakveo® (crizanlizumab-tmca) Injection 100 mg/10 mL (10 mg/ml) For Intravenous Infusion After Dilution. 1 Single-dose Vial. Discard Unused Portion. Novartis (Seg101 02)

ADAKVEO is an injection medication used for intravenous infusion after dilution. Each 10 mL vial contains 100 mg of crizanlizumab-tmca, citric acid, poloxamer 188, sodium citrate, sucrose, and water for injection. Before using the injection, ensure that there is no acceleration or particular matter. It is recommended to store and transport the vial refrigerated at 2°C to 8°C (36°F to 46°F) while protected from light. For more information, please visit their website or call as indicated.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.